These results show that BPC157 conforms to the metabolic process of peptide drugs, further proving its metabolic safety
While the peptides lack of IGF-1 effects and glucose impact suggests minimal interaction potential, comprehensive medication review remains appropriate, particularly for drugs affecting metabolism or blood glucose
Published Phase 2 clinical trial data used doses of 1mg, 4mg, 8mg, and 12mg administered weekly via subcutaneous injection
Even if a peptide seems tolerated in the short term, chronic or repeated use could produce side effects that take months or years to manifest
KLOW Peptide Blend Clinical Evidence Context No direct evidence: No published human or animal trial has evaluated the four-peptide KLOW combination
doi: 10.1016/j.tice.2025.102837